Skip to main content
Fig. 4 | Molecular Medicine

Fig. 4

From: Administration of zoledronic acid alleviates osteoporosis in HIV patients by suppressing osteoclastogenesis via regulating RANKL expression

Fig. 4

ELISA analysis showed that the expression of RANKL, SMAD3 and PRKACB was remarkably decreased in the serum of HIV patients receiving tenofovir treatment. a ZOL treatment suppressed the expression of RANKL in the serum of HIV patients receiving tenofovir treatment. b ZOL treatment suppressed the expression of SMAD3 in the serum of HIV patients receiving tenofovir treatment. c ZOL treatment suppressed the expression of PRKACB in the serum of HIV patients receiving tenofovir treatment

Back to article page

Molecular Medicine

ISSN: 1528-3658